Arrowhead Pharmaceuticals (ARWR) director reports planned insider stock sales

Q: What insider transaction did Arrowhead Pharmaceuticals (ARWR) report in this Form 4?

The filing reports that director William Waddill sold shares of Arrowhead Pharmaceuticals, Inc. common stock in several open-market transactions on 12/19/2025 .

Q: How many Arrowhead Pharmaceuticals (ARWR) shares did the director sell on 12/19/2025?

On 12/19/2025 , William Waddill sold 2,416 shares, 5,451 shares, and 500 shares of Arrowhead Pharmaceuticals common stock in three separate transactions.

Q: What prices did the Arrowhead Pharmaceuticals (ARWR) shares sell for in the reported trades?

The weighted average prices were $66.66 for 2,416 shares (with trades from $66.52 to $67.29), $68.01 for 5,451 shares (with trades from $67.58 to $68.48), and $68.53 for 500 shares (with trades from $68.51 to $68.56).

Q: Does the filing provide price ranges for the Arrowhead Pharmaceuticals (ARWR) insider sales?

Yes. The filing notes that the reported prices are weighted averages and that the shares were sold in multiple transactions within specified price ranges for each block of shares.

Filing Impact

(High)

Filing Sentiment

(Negative)

Form Type

Rhea-AI Filing Summary

Arrowhead Pharmaceuticals, Inc. director William Waddill reported open-market sales of company stock under a pre-arranged Rule 10b5-1 trading plan. On 12/19/2025, he sold 2,416 shares of common stock at a weighted average price of $66.66, with individual trades between $66.52 and $67.29. On the same date, he sold an additional 5,451 shares at a weighted average price of $68.01, with trades between $67.58 and $68.48, and 500 shares at a weighted average price of $68.53, with trades between $68.51 and $68.56. After these transactions, Waddill beneficially owned 56,563 shares of Arrowhead Pharmaceuticals common stock, including shares underlying previously reported restricted stock units that remain subject to vesting conditions.

Insider Trade Summary

Net Seller: 8,367 shares ($566,038)

Net Sell 3 txns

Insider Waddill William D.

Role Director

Sold 8,367 shs ($566K)

Type	Security	Shares	Price	Value
Sale	Common Stock	2,416	$66.66	$161K
Sale	Common Stock	5,451	$68.01	$371K
Sale	Common Stock	500	$68.53	$34K

Holdings After Transaction: Common Stock — 62,514 shares (Direct)

Footnotes (1)

Shares were sold pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $66.52 to $67.29, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4. Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person, a portion of which are still subject to certain vesting conditions. The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $67.58 to $68.48, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4. The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $68.51 to $68.56, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4.

Form 4 Insider Transactions: What Each Field Means →

12/23/2025 - 06:01 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Waddill William D.

(Last)

(First)

(Middle)

177 E. COLORADO BLVD

SUITE 700

(Street)

PASADENA

91105

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
ARROWHEAD PHARMACEUTICALS, INC. [ ARWR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
12/19/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	12/19/2025		S		2,416⁽¹⁾	D	$66.66⁽²⁾	62,514⁽³⁾	D
Common Stock	12/19/2025		S		5,451⁽¹⁾	D	$68.01⁽⁴⁾	57,063⁽³⁾	D
Common Stock	12/19/2025		S		500⁽¹⁾	D	$68.53⁽⁵⁾	56,563⁽³⁾	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. Shares were sold pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.

2. The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $66.52 to $67.29, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4.

3. Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person, a portion of which are still subject to certain vesting conditions.

4. The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $67.58 to $68.48, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4.

5. The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $68.51 to $68.56, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4.

Remarks:

	/s/William Waddill	12/23/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did Arrowhead Pharmaceuticals (ARWR) report in this Form 4?

The filing reports that director William Waddill sold shares of Arrowhead Pharmaceuticals, Inc. common stock in several open-market transactions on 12/19/2025.

How many Arrowhead Pharmaceuticals (ARWR) shares did the director sell on 12/19/2025?

On 12/19/2025, William Waddill sold 2,416 shares, 5,451 shares, and 500 shares of Arrowhead Pharmaceuticals common stock in three separate transactions.

What prices did the Arrowhead Pharmaceuticals (ARWR) shares sell for in the reported trades?

The weighted average prices were $66.66 for 2,416 shares (with trades from $66.52 to $67.29), $68.01 for 5,451 shares (with trades from $67.58 to $68.48), and $68.53 for 500 shares (with trades from $68.51 to $68.56).

How many Arrowhead Pharmaceuticals (ARWR) shares does the reporting person own after these sales?

Following the reported transactions, William Waddill beneficially owned 56,563 shares of Arrowhead Pharmaceuticals common stock, including shares underlying previously reported restricted stock units subject to vesting.

Were the Arrowhead Pharmaceuticals (ARWR) insider sales made under a Rule 10b5-1 trading plan?

Yes. The filing states that the shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934.

Does the filing provide price ranges for the Arrowhead Pharmaceuticals (ARWR) insider sales?

Yes. The filing notes that the reported prices are weighted averages and that the shares were sold in multiple transactions within specified price ranges for each block of shares.